

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2008

DEL CATH SYSTEMS, INC.

(Exact Name of Registrant as Specified in Charter)

DELAWARE

(State of Incorporation)

001-16133

(Commission
File Number)

06-1245881

(IRS Employer
Identification No.)

600 FIFTH AVENUE, 23rd FLOOR
NEW YORK, NEW YORK

(Address of Principal Executive Offices)

10020

(Zip Code)

Registrant's telephone number, including area code: (212) 489-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective December 11, 2008 (the “Effective Date”), the Board of Directors of Delcath Systems, Inc. (the “Company”) elected Pamela R. Contag as a Director. Dr. Contag’s election was recommended by the Nominating & Governance Committee and approved by the unanimous action of the full Board of Directors. See Exhibit 99.1 attached hereto for biographical information about Dr. Contag.

Dr. Contag will receive standard director fees and benefits. In addition, she was awarded on the Effective Date under the Company’s 2004 Stock Incentive Plan (the “Plan”) options to purchase 75,000 shares of the Company’s common stock at an exercise price per share equal to the Fair Market Value thereof on the Effective Date determined in accordance with the Plan. There are no other material transactions between Dr. Contag and the Company.

Effective December 13, 2008, the Company appointed Barbra C. Keck, 31, as the Company’s Controller. Ms. Keck received her MBA in accounting in August of this year from Baruch College. Most recently, Ms. Keck has been an audit assistant with Deloitte & Touche LLP since September 2008, prior to which she was a student for her MBA since September 2006. In addition, from 2006 until 2008, Ms. Keck was an assistant to the Vice President and Dean of Baruch College. From 2005 to 2006, Ms. Keck was a donor relations and communications manager at Young Audiences New York, a nonprofit organization that works with educational systems, the arts community and private and public sectors to provide arts education to children and, from 2003 to 2005, she was a manager of arts and cultural events for the University of Dayton.

Item 9.01. Financial Statements and Exhibits

<u>Exhibit</u> <u>Number</u>	<u>Description</u>
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 16, 2008

DELCATH SYSTEMS, INC.

By: /s/ Richard L. Taney

Name: Richard L. Taney

Title: Chief Executive Officer

Delcath Adds Dr. Pamela R. Contag to Its Board of Directors

NEW YORK, December 16, 2008 - Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Pamela R. Contag, Ph.D. to Delcath's Board of Directors. Dr. Contag is a proven company executive with extensive experience working with international and domestic investors.

Dr. Contag founded Cobalt Technologies, Inc. in 2006 and served as CEO. Prior to starting Cobalt, she founded Xenogen Corporation, a biotechnology company specializing in technology and services for preclinical drug development and testing. She served as President and Director of Xenogen from 1995 to 2006. Xenogen, which became a public company in 2004, was acquired by Caliper Life Sciences in 2006. Xenogen Corporation was listed as one of the "Top 25 Young Businesses" by Fortune Small Business and twice received the "R&D 100 Award." Dr. Contag was also recognized as one of the "Top 25 Women in Small Business" by Fortune magazine.

Dr. Contag received her Ph.D. in Microbiology from the University of Minnesota Medical School and completed her postdoctoral training at Stanford University School of Medicine. Dr. Contag is a consulting Professor at the Stanford School of Medicine and is widely published in the field of non-invasive molecular and cellular imaging.

Richard L. Taney, President and Chief Executive Officer of Delcath, welcomes Dr. Contag onto the Board, stating, "Delcath continues to add strategic insight and expertise to our Board of Directors as we sharpen our focus on the completion of our trial and approval of the Delcath PHP System. Dr. Contag's biotech, pharmaceutical and testing experience will be particularly relevant as we prepare for meetings with the FDA regarding regulatory approvals and ultimately, commercialization. Her extensive industry relationships will provide us with multiple opportunities to expand the recognition and value of the Delcath technology. The recent clinical milestones and additions of key management and Board members over the past six months, have positioned our Company well, as enrollment continues to accelerate and we move towards completion of our Phase III trial."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure

regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

#

Company Contact:

Delcath Systems, Inc.
Richard Taney
(212) 489-2100
info@delcath.com

Public Relations Contact:

Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
rwagge@rubenstein.com